Federal regulators on Tuesday told drugmakers Novo Nordisk and Eli Lilly to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss medications. The U.S. Food and Drug Administration said a comprehensive review “found no increased” risk related to suicide among users of the GLP-1 drugs for obesity, including Novo Nordisk’s Wegovy and Saxenda and Eli Lilly’s Zepbound. A preliminary review in January 2024 showed no link between the drugs and